Doctor ratings and reviews have gotten a bad name, especially from doctors. There are concerns about their validity and usefulness. And while I share these worries I also believe ratings and reviews are important and have the potential to become much more prominent and useful over time.
I’m encouraged that some healthcare providers are reversing course and starting to publish ratings and reviews on their own websites. University of Utah is doing it, the Cleveland Clinic is considering following along, and others are also starting to think about it (Hospitals get into doc rating business).
That’s a good sign that patient reviews are going mainstream. We’ll be even better informed once the sites include other information that’s becoming available, such as the recently released Medicare claims data and complementary data on quality and cost from the private market, such as information that will be provided by the Robert Wood Johnson foundation-sponsored DOCTOR Project.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
—
By healthcare consultant David E. Williams of the Health Business Group
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
